Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
Mazdutide is a dual GLP-1 and glucagon agonist that hit 20% weight loss at 60 weeks in Phase 3 trials. NMPA-approved in China but not yet available through Western pharmacies. The glucagon component adds thermogenic fat burning that GLP-1-only drugs can't match.
3mg · Weekly
Summary: Add 2mL BAC water to your 100mg vial. Draw to 6.0 units on a U-100 syringe for a 3mg dose. This vial will last 33 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 3mg | Weekly |
| Moderate | 6mg | Weekly |
| Aggressive | 9mg | Weekly |
The 100 mg vial format is unusual. Most peptides come in 5 mg or 10 mg vials; mazdutide's high concentration means reconstitution math is less forgiving. With 2 mL bacteriostatic water in a 100 mg vial, you get 50 mg/mL. That's 5x more concentrated than a typical peptide reconstitution. At that concentration, your doses look like this on a 100-unit insulin syringe: 3 mg = 0.06 mL = 6 units; 6 mg = 0.12 mL = 12 units; 9 mg = 0.18 mL = 18 units. Double-check your math every time. An accidental 60 units instead of 6 units would deliver 30 mg, ten times the starting dose. Titration pace matters more than most users expect. The 4-week hold at each dose level isn't just about GI tolerance. It lets the drug reach steady state given that variable 6 to 28 day half-life. Rushing the escalation guarantees worse nausea and unpredictable serum levels. Store lyophilized powder at 2 to 8 degrees Celsius. After reconstitution, refrigerate and use within 4 weeks. Discard if the solution looks cloudy or you see particles.
Dosing based on GLORY-1 Phase 3 Trial: mazdutide in Chinese adults with obesity (NEJM 2025) — 10 published references.View all sources →
Cross-check your Mazdutide reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Mazdutide is a dual GLP-1 and glucagon agonist that hit 20% weight loss at 60 weeks in Phase 3 trials. NMPA-approved in China but not yet available through Western pharmacies. The glucagon component adds thermogenic fat burning that GLP-1-only drugs can't match.